Please disable your Ad Blocker to better interact with this website.

Pill To Increase Women’s Sex Drive Gains Federal Approval

America will never be the same.

The Food and Drug Administration voted Thursday to recommend approval for a drug that would increase a woman’s sex drive, The New York Times reports.

The drug, Flibanserin, is a pink pill meant to be taken daily. It had been denied two times by the FDA, but the third time was the charm. The drug makers have been directed to work to lower the drug’s side effects, which can include sleepiness, low blood pressure, nausea, fainting and dizziness.

After the second refusal from the FDA, a group of advocates rallied around the little pink pill. They founded a group called “Even The Score” and began gathering signatures on a petition.

The pill had been rejected in 2010 and 2013. The women who participated in the trial found they had only one more “sexually satisfying event” per month as women on the placebo.

Groups like the National Organization for Women and Even The Score have claimed sexism, arguing that the pill was receiving more scrutiny than similar pills for men. They stress that Hypoactive Sexual Desire Disorder is a real problem that deserves real treatment.

“The FDA Advisory Committee made history for women’s sexual health today by choosing to respect the science and stand with the millions of American women suffering from HSDD by opening the door to medical treatment options for their most common sexual dysfunction,” Even The Score said in a statement. “They rejected an unsustainable status quo where women have ZERO medical treatment options for their condition – while at the same time men enjoy 26 options marketed for their own sexual dysfunction.”

After the announcement, Even The Score had reason to celebrate.

The @US_FDA made #HERstory for women today! #Flibanserin gets stamp of approval from independent FDA panel. More: http://t.co/v0ycFvcN2d

— Even The Score (@Eventhescore) June 4, 2015

 

Even The Score said the FDA will deliver it’s final ruling in August.

Follow Casey on Twitter and like him on Facebook

Content created by The Daily Caller News Foundation is available without charge to any eligible news publisher that can provide a large audience. For licensing opportunities of our original content, please contact licensing@dailycallernewsfoundation.org.



 

Posting Policy

We have no tolerance for comments containing violence, racism, vulgarity, profanity, all caps, or discourteous behavior. Thank you for partnering with us to maintain a courteous and useful public environment where we can engage in reasonable discourse.

Trending Now on BarbWire.com

Send this to a friend